124 related articles for article (PubMed ID: 15559052)
1. Genetics of malignant pleural mesothelioma: molecular markers and biologic targets.
Bueno R; Gordon GJ
Thorac Surg Clin; 2004 Nov; 14(4):461-8. PubMed ID: 15559052
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional profiling of mesothelioma using microarrays.
Gordon GJ
Lung Cancer; 2005 Jul; 49 Suppl 1():S99-S103. PubMed ID: 15950812
[TBL] [Abstract][Full Text] [Related]
4. Current concepts in malignant pleural mesothelioma.
Kaufman AJ; Pass HI
Expert Rev Anticancer Ther; 2008 Feb; 8(2):293-303. PubMed ID: 18279069
[TBL] [Abstract][Full Text] [Related]
5. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up.
Destro A; Ceresoli GL; Baryshnikova E; Garassino I; Zucali PA; De Vincenzo F; Bianchi P; Morenghi E; Testori A; Alloisio M; Santoro A; Roncalli M
Lung Cancer; 2008 Mar; 59(3):369-76. PubMed ID: 17920725
[TBL] [Abstract][Full Text] [Related]
6. Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Edenfield HR; Glickman JN; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):447-54. PubMed ID: 17253596
[TBL] [Abstract][Full Text] [Related]
8. Molecular changes in mesothelioma with an impact on prognosis and treatment.
Jean D; Daubriac J; Le Pimpec-Barthes F; Galateau-Salle F; Jaurand MC
Arch Pathol Lab Med; 2012 Mar; 136(3):277-93. PubMed ID: 22372904
[TBL] [Abstract][Full Text] [Related]
9. Molecular prognostic markers in malignant mesothelioma.
Kumar P; Kratzke RA
Lung Cancer; 2005 Jul; 49 Suppl 1():S53-60. PubMed ID: 15950802
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and staging of malignant pleural mesothelioma].
Sohrab S; Konietzko N
Pneumologie; 2002 Jun; 56(6):382-7. PubMed ID: 12063622
[TBL] [Abstract][Full Text] [Related]
11. Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?
Mlika M; Ayadi-Kaddour A; Ksantini M; Bouraoui S; Mzabi S; El Mezni F
J Immunoassay Immunochem; 2013; 34(2):111-25. PubMed ID: 23537297
[TBL] [Abstract][Full Text] [Related]
12. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
Falleni M; Pellegrini C; Marchetti A; Roncalli M; Nosotti M; Palleschi A; Santambrogio L; Coggi G; Bosari S
Lung Cancer; 2005 May; 48(2):211-6. PubMed ID: 15829320
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs dysregulation in human malignant pleural mesothelioma.
Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model.
Sudo H; Tsuji AB; Sugyo A; Kohda M; Sogawa C; Yoshida C; Harada YN; Hino O; Saga T
Genomics; 2010 Apr; 95(4):210-6. PubMed ID: 20153416
[TBL] [Abstract][Full Text] [Related]
16. [Clonal chromosome abnormalities in a case of pleural mesothelioma].
Pegoraro M; Bersi M; Gasparini C; Cardini G; Ruffoni A
Arch Sci Med (Torino); 1973; 130(2):125-30. PubMed ID: 17342920
[TBL] [Abstract][Full Text] [Related]
17. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes.
Hoang CD; Zhang X; Scott PD; Guillaume TJ; Maddaus MA; Yee D; Kratzke RA
Cancer Res; 2004 Oct; 64(20):7479-85. PubMed ID: 15492273
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets.
Motadi LR; Misso NL; Dlamini Z; Bhoola KD
Int Immunopharmacol; 2007 Dec; 7(14):1934-47. PubMed ID: 18039530
[TBL] [Abstract][Full Text] [Related]
19. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma.
Davidson B; Reich R; Lazarovici P; Flørenes VA; Risberg B; Nielsen S; Sert B; Bedrossian C
Lung Cancer; 2004 May; 44(2):159-65. PubMed ID: 15084380
[TBL] [Abstract][Full Text] [Related]
20. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
